Matthew Henn Biography and Net Worth

Insider of Seres Therapeutics

Senior Vice President, Head of Drug Discovery & Bioinformatics

Matthew Henn has over 16 years of combined research experience in microbial ecology, genomics, and bioinformatics that span both environmental and infectious disease applications. Prior to joining Seres Therapeutics he was the Director of Viral Genomics and Assistant Director of the Genome Sequencing Center for Infectious Diseases at the Broad Institute of MIT and Harvard. Matt is an expert in the development, implementation, and application of various genomic technologies to the study of microbial populations and their metabolic function. He has over 60 peer-reviewed publications in microbiology and bioinformatics and he has led multiple large-scale international genomic projects. He has served as a consultant for the WHO’s Grand Challenges in Genomics for Public Health in Developing Countries, is a scientific advisor for NIH’s Viral Pathogen Bioinformatics Resource Center, and serves on the editorial board of Genome Medicine. Matt earned his Ph.D. in Ecosystem Sciences from the University of California at Berkeley, where he was a NASA Earth Systems Sciences Fellow, and trained as a NSF Postdoctoral Fellow in Microbiology at Duke University.

What is Matthew R. Henn's net worth?: The estimated net worth of Matthew R. Henn is at least $29,765.10 as of February 18th, 2025. Dr. Henn owns 4,222 shares of Seres Therapeutics stock worth more than $29,765 as of May 29th. This net worth approximation does not reflect any other assets that Dr. Henn may own. Additionally, Dr. Henn receives a salary of $643,830.00 as Insider at Seres Therapeutics. Learn More about Matthew R. Henn's net worth.
How old is Matthew R. Henn?: Dr. Henn is currently 49 years old. There are 5 older executives and no younger executives at Seres Therapeutics. The oldest executive at Seres Therapeutics is Mr. Thomas J. DesRosier Esq., J.D., Chief Legal Officer, Executive VP & Secretary, who is 69 years old. Learn More on Matthew R. Henn's age.
What is Matthew R. Henn's salary?: As the Insider of Seres Therapeutics, Inc., Dr. Henn earns $643,830.00 per year. There are 3 executives that earn more than Dr. Henn. The highest earning executive at Seres Therapeutics is Mr. Eric D. Shaff M.B.A., President, CEO & Director, who commands a salary of $1,020,000.00 per year. Learn More on Matthew R. Henn's salary.
How do I contact Matthew R. Henn?: The corporate mailing address for Dr. Henn and other Seres Therapeutics executives is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. Seres Therapeutics can also be reached via phone at (617) 945-9626 and via email at ctanzi@serestherapeutics.com. Learn More on Matthew R. Henn's contact information.
Has Matthew R. Henn been buying or selling shares of Seres Therapeutics?: Matthew R. Henn has not been actively trading shares of Seres Therapeutics during the last ninety days. Most recently, Matthew R. Henn sold 197 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $16.20, for a transaction totalling $3,191.40. Following the completion of the sale, the insider now directly owns 4,222 shares of the company's stock, valued at $68,396.40. Learn More on Matthew R. Henn's trading history.
Who are Seres Therapeutics' active insiders?: Seres Therapeutics' insider roster includes Thomas DesRosier (EVP), Matthew Henn (Insider), Eric Shaff (https://ir.pragroup.com/board-of-directors?item=14), and Teresa Young (Executive Vice President, Chief Commercial and Strategy Officer). Learn More on Seres Therapeutics' active insiders.
Are insiders buying or selling shares of Seres Therapeutics?: During the last twelve months, insiders at the biotechnology company sold shares 13 times. They sold a total of 3,569 shares worth more than $61,314.60. The most recent insider tranaction occured on February, 18th when insider Matthew R Henn sold 197 shares worth more than $3,191.40. Insiders at Seres Therapeutics own 4.7% of the company. Learn More about insider trades at Seres Therapeutics.
Information on this page was last updated on 2/18/2025.

Matthew R. Henn Insider Trading History at Seres Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/18/2025	Sell	197	$16.20	$3,191.40	4,222

Matthew R. Henn Buying and Selling Activity at Seres Therapeutics

Seres Therapeutics Company Overview

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $7.03

$7.00

$7.31

50 Day Range

MA: $9.85

$6.77

$15.10

2 Week Range

Now: $7.03

$6.53

$30.60

Volume

67,071 shs

Average Volume

145,867 shs

Market Capitalization

$61.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.89

Matthew Henn Biography and Net Worth

What is Matthew R. Henn's net worth?

How old is Matthew R. Henn?

What is Matthew R. Henn's salary?

How do I contact Matthew R. Henn?

Has Matthew R. Henn been buying or selling shares of Seres Therapeutics?

Who are Seres Therapeutics' active insiders?

Are insiders buying or selling shares of Seres Therapeutics?